Amarin Corporation plc (AMRN)
NASDAQ: AMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMRN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $444.39M
- Forward P/E
- 10.79
- EPS (TTM)
- -$0.80
- Dividend yield
- None
- 52-week range
- 10.56 – 17.31
- Day range
- 10.56 – 11.30
- Volume / Avg
- 177.91K / 79.50K
- Beta
- —
- Shares outstanding
- 42.04M
52-week range
AMRN stock today
Shares of Amarin (AMRN) finished lower on Nov 20 at $10.57, a drop of 6.13% or $0.69 per share, versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 177.91K shares, a sign of unusually heavy trading. At this level, AMRN sits near the bottom of its 52-week range of $10.56 to $17.31: 38.9% below the high, set on Jan 23, 2026 and 0.1% above the low.
AMRN is down 24.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.5%. Amarin has posted a net loss over the last twelve months (EPS of -$0.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Amarin
Company profileAmarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Aaron D. Berg
- Headquarters
- Dublin
- Employees
- 80
- Website
- amarincorp.com
Financial highlights
Full financialsIn fiscal 2025, Amarin generated $213.6 million in revenue, down 6.5% from fiscal 2024, its first annual decline since 2024. Amarin reported a net loss of $38.8 million, compared with a loss of $82.2 million a year earlier. Gross margin was 56.6% (up from 35.6%) and operating margin -23.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $213.65M | $228.61M | $306.91M | $369.19M | $583.19M |
| Growth | -6.55% | -25.51% | -16.87% | -36.69% | -5.03% |
| Net income | $-38.80M | $-82.18M | $-59.11M | $-105.80M | $7.73M |
| EPS (diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$13.00+22.99%
- Strong buy 0
- Buy 0
- Hold 0
- Sell 0
- Strong sell 1
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $0.00 vs $-0.28
- Surprise
- +100.00%
AMRN news
All AMRN news- Amarin Corporation plc Reports Resignation of Director Patrice Bonfiglio Effective November 16, 2026Nasdaq
- Amarin: 3 Key Takeaways for Long-Term InvestorsNasdaqAMRN, ET
- Amarin's Q3 Earnings Beat Estimates, Revenues Miss MarkNasdaqAMRN, TGTX, IOVA, AMRX
- Amarin (AMRN) Q3 2026 Earnings Call TranscriptNasdaqAMRN, ET
- What Amarin (AMRN) Said on Its Q3 Earnings CallNasdaq
- Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net IncomeGlobeNewswire
- Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)GlobeNewswire
- Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026GlobeNewswire
Amarin peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs AMRN |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs AMRN |
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs AMRN |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs AMRN |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs AMRN |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs AMRN |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs AMRN |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs AMRN |
Indexes, lists and sector
Amarin stock FAQ
What is Amarin's stock price today?
AMRN last traded at $10.57 as of Nov 20, 4:00 PM EST, down 6.13% on the day. Prices are delayed at least 15 minutes.
Does Amarin pay a dividend?
No. Amarin does not currently pay a regular cash dividend.
Who is Amarin's CEO?
Mr. Aaron D. Berg is the chief executive officer of Amarin Corporation plc, which has about 80 employees.
Has AMRN ever split its stock?
Yes. The most recent AMRN stock split was a 1-for-20 split on Apr 11, 2025, one of 3 splits on record.
What is the AMRN 52-week high?
The 52-week high for AMRN is $17.31 and the 52-week low is $10.56. The stock is currently 38.9% below its high.